Key result
VCAM-1 levels increased during acute STEMI and remained elevated at 12 months, with higher levels predicting fatal outcomes and increased severity of heart failure regardless of visceral obesity.
Why the study?
The study was conducted to evaluate adhesion molecule levels in patients with STEMI across different BMI categories during hospitalization and at 12 months after the index event.
Observational (n=153)
Elevated VCAM-1 levels during and after STEMI may serve as a biomarker for systemic inflammation and a predictor of adverse outcomes such as heart failure severity and mortality.
Objective: to study the level of adhesion molecules in patients with STEMI with different BMI at the hospital stage and 12 months after the index event. Materials and methods: the study included 126 people with STEMI who had undergone PCI and 27 people in the control group. The analysis of the level of svcam‑1 in peripheral blood at the beginning of the disease and after 12 months was carried out, BMI and waist volume were measured. An assessment of the nature and frequency of complications after STEMI was performed. Results: the levels of biomarkers of the vascular endothelial adhesion molecule type 1 increase during the acute period of stemi, statistically signifi tly decrease, but remain increased by 3.5 times 12 months after the index event compared with the initial values. There was no association of VCAM‑1 with visceral obesity in the groups of our patients. Vascular endothelial adhesion molecules of type 1 increase in patients with a fatal outcome, as well as with an increase in the severity of OSN and CHF. Thus, VCAM 1 can be a predictor of an unfavorable outcome of AMI. Conclusions: the article presents the study of a marker of systemic inflammation VCAM‑11 in patients with STEMI with various types of obesity or BMI at the stage of hospitalization and outpatient follow‑up during the year. The determination of the VCAM‑1 level can be used to assess the intensity of the inflammatory process and the risk of adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Zakovryashina et al. (2021) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=153). STEMI and varying Body Mass Index (BMI) vs. Control group was evaluated on Levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) and association with complications. VCAM-1 levels increased during acute STEMI and remained elevated at 12 months, with higher levels predicting fatal outcomes and increased severity of heart failure regardless of visceral obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: